Q32 Bio Secures $55M Private Placement at $8.00 Per Share, Extending Financial Runway
QTTB has more than doubled off its 52-week low of $1.345.
Summary
Q32 Bio announced a $55 million private placement, selling common stock and pre-funded warrants at $8.00 per share, a premium to its current market price. This substantial capital raise, representing nearly half of the company's market cap, significantly extends its financial runway. The financing, led by prominent biotech investors including BVF Partners, RA Capital, and OrbiMed, signals strong investor confidence in the clinical-stage biotechnology company. This follows a series of capital raises and recent Q1 results where the company indicated securing funding to extend its runway. The funds will support the ongoing Phase 2 program for bempikibart in alopecia areata.
At the time of this announcement, QTTB was trading at $7.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.2M. The 52-week trading range was $1.35 to $8.05. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.